XTL Biopharmaceuticals
XTLB
6 hedge funds and large institutions have $1.69M invested in XTL Biopharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.
629% more capital invested
Capital invested by funds: $232K → $1.69M (+$1.46M)
50% more funds holding
Funds holding: 4 → 6 (+2)
0% more ownership
Funds ownership: 0.02% → 0.02% (+0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$66.4K |
| 2 |
SW
SteelPeak Wealth
Woodland Hills,
California
|
+$49.5K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$12.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$9.63K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NC
1
Noked Capital
Tel Aviv,
Israel
| $662K | – | – | – |
|
|
NI
2
Noked Israel
Ramat Hasharon,
Israel
| $662K | – | – | – |
|
|
3
Morgan Stanley
New York
| $180K | -$9.63K | -699 | -5% |
|
|
4
Renaissance Technologies
New York
| $129K | +$66.4K | +4,817 | +99% |
|
|
SW
5
SteelPeak Wealth
Woodland Hills,
California
| $48K | +$49.5K | +3,594 | New |
|
|
6
UBS Group
Zurich,
Switzerland
| $12K | +$12.1K | +881 | New |
|
XTLB Hedge Fund Activity: Q1 2021 in Review
6 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q1 2021, worth a combined $1.69M — up 629% from $232K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new XTLB positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $66.4K. The largest seller was Morgan Stanley, cutting an estimated $9.63K.
- 6 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q1 2021, up from 4 in Q4 2020.
- Funds reported $1.69M of XTL Biopharmaceuticals stock for Q1 2021, up 629% quarter-over-quarter.
- 2 funds opened new XTL Biopharmaceuticals positions in Q1 2021 and 0 closed out, a net change of +2 holders.
- The largest XTL Biopharmaceuticals buyer in Q1 2021 was Renaissance Technologies, an estimated $66.4K added.
- The largest XTL Biopharmaceuticals seller in Q1 2021 was Morgan Stanley, an estimated $9.63K sold.
Based on aggregated 13F filings for Q1 2021.